Nile Therapeutics, Inc.

Nile Therapeutics is a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular disease and other areas of unmet medical need.

CD-NP is a novel rationally designed chimeric natriuretic peptide in clinical studies for an initial indication of acute decompensated heart failure. » More

May 15, 2009 - Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA » Read
May 14, 2009 - Nile Therapeutics Reports 2009 First Quarter Financial Results » Read
March 27, 2009 - Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure » Read
March 18, 2009 - Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives » Read
March 9, 2009 - Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009 » Read


	Event:	Nile Therapeutics Q4 Earnings Call
	Date:	Tuesday, March 10, 2009
	Time:	4:30 PM ET
	Webcast:

Interested investors or potential investors may conveniently receive E-mail alert messages whenever certain new company information is posted to this site. To automatically receive Nile Therapeutics, Inc. e-mail alerts, enter your e-mail address and click on the Subscribe button.